Our Goal: A Cure for Rett
All of us at the Rett Syndrome Research Trust (RSRT) want a cure for Rett syndrome as urgently as you do. During the past 12 years, with the support of dedicated Rett families, we’ve advanced the most promising curative approaches. Every single company pursuing a cure for Rett is able to do so because they leveraged discoveries and resources that were incubated with RSRT funding.
Now is the time to leverage the momentum and excitement that surrounds Rett research by doubling down and expanding our efforts.
We will not rest until we have a cure.
Recently diagnosed?
We’re here to help
Getting a Rett syndrome diagnosis is one of the hardest things you’ll ever face. We know this first-hand. We’re parents too. Emotions can run the gamut and it can all seem overwhelming. You’re worried about your child and your family. You are reading everything you can get your hands on but you are not sure how to interpret it or if it's relevant.
Attacking Rett Syndrome
From Every Angle
From 2017 to 2020 we carried out Roadmap to a Cure, a research plan that identified and advanced six therapeutic strategies targeting the root cause of Rett Syndrome.
CURE 360 is the blueprint for how we now drive those advances into a coordinated, full-on attack on Rett.
Take Action
Every donation made to RSRT has occurred because a Rett family took action. If your child, grandchild, niece, godchild, or child of your close friend has Rett syndrome, we need your help. Please join our effort.
Recent News
Imagine Revolutionizing Your Child’s Clinical Care
In 2022 RSRT will launch the Rett Syndrome Global Registry, a parent/caregiver-driven registry that taps into your valuable day-to-day experience with Rett, provides new tools to manage your child’s symptoms and needs, while advancing research. The Registry Pioneer program will give you early access and let you enter data right away, thereby allowing the registry to launch with a foundational dataset and be of immediate use.
MECP2 Duplication Syndrome
MECP2 Duplication syndrome (MDS) is caused by a genetic error that duplicates a section of the X chromosome that includes the MECP2 gene. The MECP2 Duplication Syndrome Fund at RSRT, created in 2010, puts the intellectual and scientific resources of RSRT immediately to work for the MDS community. The Fund exclusively supports research aimed at reversing MDS. 100% of every dollar contributed is invested in research — not a single penny goes to overhead.
